OncoMatch

OncoMatch/Clinical Trials/NCT07033026

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Is NCT07033026 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including NGM120 Q4W and NGM120 Q8W for colorectal cancer.

Phase 2RecruitingNGM Biopharmaceuticals, IncNCT07033026Data as of Jun 2026

Treatment: NGM120 Q4W · NGM120 Q8WA multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

NGM120 Q4WNGM120 Q8W

Cancer type

Colorectal Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • NGM Clinical Study Site · Laredo, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07033026 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify